| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.39 | 6e-11 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.22 | 2e-10 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.39 | 2e-09 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-07 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-07 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.3 | 2e-06 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |